Moxifloxacin-d3-1 (hydrochloride)

Moxifloxacin-d3-1 (hydrochloride)

• CAS Number: 1246816-75-0
• UNSPSC Description: Moxifloxacin-d3-1 hydrochloride (BAY 12-8039-d3-1) is a deuterium labeled Moxifloxacin (HY-66011A). Moxifloxacin is an orally active 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia[1][2][3].
• Target Antigen: Antibiotic; Bacterial; Isotope-Labeled Compounds
• Type: Isotope-Labeled Compounds
• Related Pathways: Anti-infection;Others
• Applications: COVID-19-immunoregulation
• Field of Research: Infection
• Solubility: 10 mM in DMSO
• Smiles: [2H]C([2H])([2H])OC1=C2N(C3CC3)C=C(C(C2=CC(F)=C1N4C[C@@]5([H])[C@@](NCCC5)([H])C4)=O)C(O)=O.Cl
• Molecular Weight: 440.91
• References & Citations: [1]Culley, C.M., et al., Moxifloxacin: clinical efficacy and safety. Am J Health Syst Pharm, 2001. 58(5): p. 379-88.|[2]Balfour JA, et al. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs. 2000 Jan;59(1):115-39.|[3]Grayo S, et al. Comparison of the in vitro efficacies of moxifloxacin and amoxicillin against Listeria monocytogenes. Antimicrob Agents Chemother. 2008 May;52(5):1697-702.|[4]Ioannidis O, et al. Effect of moxifloxacin on survival, lipid peroxidation and inflammation in immunosuppressed rats with soft tissue infection caused by Stenotrophomonas maltophilia. Microbiol Immunol. 2014 Feb;58(2):96-102.|[5]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-246.
• Shipping Conditions: Room temperature
• Storage Conditions: 4°C (Powder, sealed storage, away from moisture)
• Clinical Information: No Development Reported